POLR2A Antibody (Phospho-Ser1619) (OAAF00054)

• Product Number: OAAF00054
• Name: POLR2A Antibody (Phospho-Ser1619) (OAAF00054)
• Molecular Weight: 217 kDa
• NCBI Gene Id: 5430
• Host: Rabbit
• Clonality: Polyclonal
• Gene Full Name: RNA polymerase II subunit A
• Alias Symbols: DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit;DNA-directed RNA polymerase II subunit A;DNA-directed RNA polymerase II subunit RPB1;DNA-directed RNA polymerase III largest subunit;hRPB220;hsRPB1;NEDHIB;POLR2;POLRA;polymerase (RNA) II (DNA directed) polypeptide A, 220kDa;polymerase (RNA) II subunit A;RNA polymerase II subunit B1;RNA-directed RNA polymerase II subunit RPB1;RPB1;RPBh1;RpIILS;RPO2;RPOL2.
• Product Format: Liquid
• Reference: Tracy Jo Pasieka, J. Virol., Aug 2006; 80: 7600 - 7612.
  Olaf R. Mook, Mol. Cancer Ther., Mar 2007; 6: 833 - 843.
  Colleen A. McMullen, J. Neurosci., Jan 2004; 24: 161.
• Description of Target: DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Largest and catalytic component of RNA polymerase II which synthesizes mRNA precursors and many functional non-coding RNAs. Forms the polymerase active center together with the second largest subunit. Pol II is the central component of the basal RNA polymerase II transcription machinery. It is composed of mobile elements that move relative to each other. RPB1 is part of the core element with the central large cleft, the clamp element that moves to open and close the cleft and the jaws that are thought to grab the incoming DNA template. At the start of transcription, a single-stranded DNA template strand of the promoter is positioned within the central active site cleft of Pol II. A bridging helix emanates from RPB1 and crosses the cleft near the catalytic site and is thought to promote translocation of Pol II by acting as a ratchet that moves the RNA-DNA hybrid through the active site by switching from straight to bent conformations at each step of nucleotide addition. During transcription elongation, Pol II moves on the template as the transcript elongates. Elongation is influenced by the phosphorylation status of the C-terminal domain (CTD) of Pol II largest subunit (RPB1), which serves as a platform for assembly of factors that regulate transcription initiation, elongation, termination and mRNA processing. Regulation of gene expression levels depends on the balance between methylation and acetylation levels of tha CTD-lysines (By similarity). Initiation or early elongation steps of transcription of growth-factors-induced immediate early genes are regulated by the acetylation status of the CTD (PubMed:24207025). Methylation and dimethylation have a repressive effect on target genes expression (By similarity).
• Reconstitution and Storage: -20°C
• Specificity: POLR2A (phospho-Ser1619) antibody detects endogenous levels of POLR2A only when phosphorylated at serine 1619.
• Application Info: WB: 1: 500~1:1000; IHC: 1:50~1:100; IF: 1:100~1:500; ELISA: 1:10000
• Immunogen: The antiserum was produced against synthesized peptide derived from human POLR2A around the phosphorylation site of Ser1619.
• Dilution: The optimal working dilution should be determined by the end user.
• Formulation: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
• Uniprot ID: P24928
• Protein Name: DNA-directed RNA polymerase II subunit RPB1
• Protein Accession #: NP_000928.1
• Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
• Gene Symbol: POLR2A
• Predicted Species Reactivity: Human|Monkey|Mouse|Rat
• Application: Enzyme-linked immunosorbent assay|Immunocytochemistry|Immunofluorescence|Immunohistochemistry|Immunohistochemistry-Paraffin|Western blot
• Image 1: COS7 cells
  
  Western blot analysis of extracts from COS7 cells treated with EGF 200ng/ml 30', using POLR2A (Phospho-Ser1619) Antibody. The lane on the right is treated with the synthesized peptide.
• Image 2: human breast carcinoma
  
  Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using POLR2A (Phospho-Ser1619) Antibody. The picture on the right is treated with the synthesized peptide.
• Image 3: HeLa cells
  
  Immunofluorescence analysis of HeLa cells treated with PMA 125ng/ml 30', using POLR2A (Phospho-Ser1619) Antibody. The picture on the right is treated with the synthesized peptide.